The UltimasterTM Clinical
Program included more than 50,000 patients covering 16 CE marked indications.
Demonstrates favourable outcomes in both complex and non-complex PCI patients.
Demonstrates Proximal Optimisation Technique is associated with improved outcomes.
Suggests that complete revascularisation is associated with better outcomes versus incomplete revascularisation.
The investigator-initiated MASTER DAPT study demonstrates that one month of DAPT was non-inferior to treatment continuation for at least 2 additional months for the occurrence of net and major adverse clinical events, and reduced major or clinically relevant non-major bleeding.
MASTER DAPT, the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™/Ultimaster™TanseiTM drug-eluting bioresorbable polymer stents (DES).
A total cohort of 4.579 patients have been randomized into this ambitious study.
The UltimasterTM Clinical Program included one of the largest, prospective worldwide registries, the e- ULTIMASTER™ with 37,198 patients. The Ultimaster™ Clinical Program² demonstrates the safe and effective use of the Ultimaster stent in different patient cohorts, representative of daily PCI practice.
Largest study to date on 1-year outcomes post-PCI, in an unselected, real-world cohort of patients enrolled in the e-ULTIMASTER registry.The aim of the study was to understand the prevalence, clinical characteristics, and 1-year outcomes of patients with complex lesions in an unselected cohort of over 35,000 patients who underwent PCI with the Ultimaster™ DES system.”
Download clinical summary
Discover our clinical evidence and case studies concerning this topic.
Featured product: Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System
Featured product: Ultimaster™ Sirolimus Eluting Coronary Stent System
Featured products: Ultimaster™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System
500 STEMI patients, randomised 1:3 vs Kaname BMS, primary endpoint TVF 12M. Published and completed
of high bleeding risk patients post bioresorbable polymer coated
with an abbReviated
versus standard DAPT
Our sales representatives are here for you.
Thank you for contacting us!
We typically respond within 2 business days and will come back to you as soon as possible.
This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public
For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.